66619-92-9

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 123-31-9 hydroquinone 

Downstream Products

• 66619-93-0 1-(4-bromobutyloxy)-4-(3-bromopropyloxy)benzene 
• 66619-82-7 4-{4-[4-(7-Oxo-6-propionyl-nonyloxy)-phenoxy]-butyl}-heptane-3,5-dione 
• 66619-80-5 1-(5,5-dipropionylpentyloxy)-4-(4,4-dipropionylbutyloxy)benzene 
• 1452855-78-5 4-(4-(ethyl(phenyl)amino)butoxy)phenol 
• 1431659-38-9 4-(4-(methyl(phenyl)amino)butoxy)phenol 

Relevant academic research and scientific papers

Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia

This study explores the possible use of reactive oxygen-activated DNA modifying agents against acute myeloid leukemia (AML). A key amine on the lead agent was investigated via cytotoxicity assays and was found necessary for potency. The two best compounds were screened via the NCI-60 cell panel. These two compounds had potency between 200 and 800 nM against many of the leukemia cancer cell types. Subsequent experiments explored activity against a transformed AML model that mimics the molecular signatures identified in primary AML patient samples. A lead compound had an IC50 of 760 nM against this AML cell line as well as a therapeutic index of 7.7 ± 3 between the transformed AML model cell line and non-cancerous human CD34+ blood stem/progenitor cells (UCB). The selectivity was much greater than the mainstays of AML treatment: doxorubicin and cytarabine. This manuscript demonstrates that this novel type of agent may be useful against AML.

ROS-Activated Compounds as Selective Anti-Cancer Therapeutics

Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.